共 50 条
- [1] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 TrialJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522Lu, ShunWang, JieYu, YanYu, XinminHu, YanpingAi, XinghaoMa, ZhiyongLi, XingyaZhuang, WuLiu, YunpengLi, WeidongCui, JiuweiWang, DongLiao, WangjunZhou, JianyingWang, ZhehaiSun, YupingQiu, XiusongGao, JieBao, YuanyuanLiang, LiangWang, Mengzhao
- [2] Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S379 - S379Shen, B.Pan, B.Wu, Y.Shi, L.Gao, J.Feng, J.
- [3] First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLCJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Wang, LijieGao, MingYang, WenyuWang, ChunyuWang, TingJing, FangfangMa, JunxunZhang, FanTao, HaitaoHu, Yi
- [4] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical TrialJAMA ONCOLOGY, 2021, 7 (05) : 709 - 717Wang, JieLu, ShunYu, XinminHu, YanpingSun, YupingWang, ZhijieZhao, JunYu, YanHu, ChunhongYang, KunyuFeng, GuoshengYing, KejingZhuang, WuZhou, JianyingWu, JingxunLeaw, Shiang JiinZhang, JingLin, XiaoLiang, LiangYang, Nong
- [5] Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC PatientsJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S317 - S318Shen, B.Pan, B.Wu, Y.Shi, L.Gao, J.Du, X.Feng, J.
- [6] Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLCANNALS OF ONCOLOGY, 2020, 31 : S816 - S817Lu, S.Yu, Y.Yu, X.Hu, Y.Ma, Z.Li, X.Zhuang, W.Liu, Y.Li, W.Cui, J.Wang, D.Liao, W.Wang, M.Zhou, J.Wang, Z.Sun, Y.Gao, J.Bao, Y.Liang, L.Wang, J.
- [7] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialNature Medicine, 2021, 27 : 1536 - 1543Hai-Qiang MaiQiu-Yan ChenDongping ChenChaosu HuKunyu YangJiyu WenJingao LiYing-Rui ShiFeng JinRuilian XuJianji PanShenhong QuPing LiChunhong HuYi-Chun LiuYi JiangXia HeHung-Ming WangWan-Teck LimWangjun LiaoXiaohui HeXiaozhong ChenZhigang LiuXianglin YuanQi LiXiaoyan LinShanghua JingYanju ChenYin LuChing-Yun HsiehMuh-Hwa YangChia-Jui YenJens SamolHui FengSheng YaoPatricia KeeganRui-Hua Xu
- [8] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialNATURE MEDICINE, 2021, 27 (09) : 1536 - +Mai, Hai-QiangChen, Qiu-YanChen, DongpingHu, ChaosuYang, KunyuWen, JiyuLi, JingaoShi, Ying-RuiJin, FengXu, RuilianPan, JianjiQu, ShenhongLi, PingHu, ChunhongLiu, Yi-ChunJiang, YiHe, XiaWang, Hung-MingLim, Wan-TeckLiao, WangjunHe, XiaohuiChen, XiaozhongLiu, ZhigangYuan, XianglinLi, QiLin, XiaoyanJing, ShanghuaChen, YanjuLu, YinHsieh, Ching-YunYang, Muh-HwaYen, Chia-JuiSamol, JensFeng, HuiYao, ShengKeegan, PatriciaXu, Rui-Hua
- [9] Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patientsANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1444Wang, Z.Zhao, J.Ma, Z.Cui, J.Shu, Y.Liu, Z.Cheng, Y.Leaw, S.Wu, Y.Ma, Y.Tan, W.Wang, J.
- [10] Tislelizumab Plus Standard Chemotherapy as First-Line Treatment in Advanced Thymic Epithelial Tumors(TETs): A Prospective, Single-Arm TrialJOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S280 - S281Zhang, L.Li, S.He, J.Gao, W.